Serum Irisin Levels, Precocious Myocardial Infarction, and Healthy Exceptional Longevity

Febbraio, 2005, Contraction-induced myokine production and release: is skeletal muscle an endocrine organ?, Exerc Sport Sci Rev, 33, 114, 10.1097/00003677-200507000-00003 Duzova, 2012, Skeletal muscle, myokines and health, Med Science, 1, 211, 10.5455/medscience.2012.01.8023 Bostrom, 2012, A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis, Nature, 481, 463, 10.1038/nature10777 Polyzos, 2013, Irisin: a renaissance in metabolism?, Metabolism, 62, 1037, 10.1016/j.metabol.2013.04.008 Spiegelman, 2013, Banting lecture 2012: regulation of adipogenesis: toward new therapeutics for metabolic disease, Diabetes, 62, 1774, 10.2337/db12-1665 Sanchis-Gomar, 2013, The skeletal muscle-metabolism axis in prostate-cancer therapy, N Engl J Med, 367, 2257 Sanchis-Gomar, 2012, Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes, J Diabetes, 4, 196 Hojlund, 2013, Irisin in obesity and type 2 diabetes, J Diabetes Complications, 27, 303, 10.1016/j.jdiacomp.2013.04.002 Sanchis-Gomar, 2014, The p38-PGC-1alpha-irisin-betatrophin axis: exploring new pathways in insulin resistance, Adipocyte, 3, 67, 10.4161/adip.27370 Elbelt, 2013, Irisin: what promise does it hold?, Curr Opin Clin Nutr Metab Care, 16, 541, 10.1097/MCO.0b013e328363bc65 Villarroya, 2013, Irisin, turning up the heat, Cell Metab, 15, 277, 10.1016/j.cmet.2012.02.010 Sanchis-Gomar, 2013, Irisinemia: a novel concept to coin in clinical medicine?, Ann Nutr Metab, 63, 60, 10.1159/000354090 Reaven, 2011, Insulin resistance: the link between obesity and cardiovascular disease, Med Clin North Am, 95, 875, 10.1016/j.mcna.2011.06.002 Kuloglu, 2014, Irisin: a potentially candidate marker for myocardial infarction, Peptides, 55C, 85, 10.1016/j.peptides.2014.02.008 Berger, 2010, Sarcopenia: prevalence, mechanisms, and functional consequences, Interdiscip Top Gerontol, 37, 94, 10.1159/000319997 Bostrom, 2014, Metabolism: irisin, the metabolic syndrome and follistatin in humans, Nat Rev Endocrinol, 10, 11, 10.1038/nrendo.2013.230 Huh, 2012, FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise, Metabolism, 61, 1725, 10.1016/j.metabol.2012.09.002 Stengel, 2013, Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index, Peptides, 39, 125, 10.1016/j.peptides.2012.11.014 Moreno-Navarrete, 2013, Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance, J Clin Endocrinol Metab, 98, E769, 10.1210/jc.2012-2749 Choi, 2013, Serum irisin levels in new-onset type 2 diabetes, Diabetes Res Clin Pract, 100, 96, 10.1016/j.diabres.2013.01.007 Liu, 2013, Lower circulating irisin is associated with type 2 diabetes mellitus, J Diabetes Complications, 27, 365, 10.1016/j.jdiacomp.2013.03.002 Park, 2013, Circulating irisin in relation to insulin resistance and the metabolic syndrome, J Clin Endocrinol Metab, 98, 4899, 10.1210/jc.2013-2373 Vamvini, 2013, Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans, Eur J Endocrinol, 169, 829, 10.1530/EJE-13-0276 Sanchis-Gomar, 2014, Inconsistency in circulating Irisin levels: what is really happening?, Horm Metab Res, 46, 1 Sanchis-Gomar, 2014, Circulating irisin levels are not correlated with BMI, age, and other biological parameters in obese and diabetic patients, Endocrine, 46, 674, 10.1007/s12020-014-0170-9 Rana, 2014, Plasma irisin levels predict telomere length in healthy adults, Age (Dordr), 36, 995, 10.1007/s11357-014-9620-9 Brouilette, 2003, White cell telomere length and risk of premature myocardial infarction, Arterioscler Thromb Vasc Biol, 23, 842, 10.1161/01.ATV.0000067426.96344.32